Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioproperties pty. ltd. - mycoplasma gallisepticum strain ts-11 - misc. vaccines or anti sera - mycoplasma gallisepticum strain ts-11 vaccine-general active 0.0 ccu/dose - immunotherapy - poultry layers (eggs for human consump) | caged layers | chickens | chooks | hen - chronic respiratory disease | mycoplasma gallisepticum | vaccine | chronic respiratory disease (c | equine rotavirus | infectious sinusitis

Канада - Енглески - Health Canada

glaxosmithkline inc - recombinant human papillomavirus type 16 l1 protein; recombinant human papillomavirus type 18 l1 protein - suspension - 20mcg; 20mcg - recombinant human papillomavirus type 16 l1 protein 20mcg; recombinant human papillomavirus type 18 l1 protein 20mcg - vaccines

Канада - Енглески - Health Canada

merck canada inc - recombinant human papillomavirus type 6 l1 protein; recombinant human papillomavirus type 11 l1 protein; recombinant human papillomavirus type 16 l1 protein; recombinant human papillomavirus type 18 l1 protein - suspension - 20mcg; 40mcg; 40mcg; 20mcg - recombinant human papillomavirus type 6 l1 protein 20mcg; recombinant human papillomavirus type 11 l1 protein 40mcg; recombinant human papillomavirus type 16 l1 protein 40mcg; recombinant human papillomavirus type 18 l1 protein 20mcg - vaccines

Канада - Енглески - Health Canada

merck canada inc - recombinant human papillomavirus type 6 l1 protein; recombinant human papillomavirus type 11 l1 protein; recombinant human papillomavirus type 16 l1 protein; recombinant human papillomavirus type 18 l1 protein; recombinant human papillomavirus type 31 l1 protein; recombinant human papillomavirus type 33 l1 protein; recombinant human papillomavirus type 45 l1 protein; recombinant human papillomavirus type 52 l1 protein; recombinant human papillomavirus type 58 l1 protein - suspension - 30mcg; 40mcg; 60mcg; 40mcg; 20mcg; 20mcg; 20mcg; 20mcg; 20mcg - recombinant human papillomavirus type 6 l1 protein 30mcg; recombinant human papillomavirus type 11 l1 protein 40mcg; recombinant human papillomavirus type 16 l1 protein 60mcg; recombinant human papillomavirus type 18 l1 protein 40mcg; recombinant human papillomavirus type 31 l1 protein 20mcg; recombinant human papillomavirus type 33 l1 protein 20mcg; recombinant human papillomavirus type 45 l1 protein 20mcg; recombinant human papillomavirus type 52 l1 protein 20mcg; recombinant human papillomavirus type 58 l1 protein 20mcg - vaccines

Малезија - Енглески - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - human papillomavirus type 11 l1; human papillomavirus type 16 l1; human papillomavirus type 18 l1; human papillomavirus type 6 l1; human papillomavirus type 31 l1; human papillomavirus type 33 l1; human papillomavirus type 45 l1; human papillomavirus type 52 l1; human papillomavirus type 58 l1 -

Кенија - Енглески - Pharmacy and Poisons Board

human bioplazma llc h-2100 godollo transics milhaly ut 80hungary - human albumin - solution for infusion - 20%human albumin - blood substitutes and plasma protein fractions

Европска Унија - Енглески - EMA (European Medicines Agency)

gsk vaccines s.r.l. - meningococcal group a, c, w-135 and y conjugate vaccine - immunization, meningitis, meningococcal - bacterial vaccines - prefilled syringe menveo is indicated for active immunisation of adolescents (from 11 years of age) and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations. vials menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.,

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 20 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 40 microgram; hpv type 18 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: aluminium; histidine; polysorbate 80; borax; water for injections; sodium chloride - gardasil is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, and 18 (which are included in the vaccine). gardasil is indicated in males 9 through 26 years of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by hpv types 6, 11, 16, and 18 (which are included in the vaccine). *immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

csl behring ag - human cytomegalovirus immune globulin (unii: 129l90a25n) (human cytomegalovirus immune globulin - unii:129l90a25n) - human cytomegalovirus immune globulin 50 mg in 1 ml - cytomegalovirus immune globulin intravenous (human) is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart. in transplants of these organs other than kidney from cmv seropositive donors into seronegative recipients, prophylactic cmv-igiv should be considered in combination with ganciclovir. cytogam should not be used in individuals with a history of a prior severe reaction associated with the administration of this or other human immunoglobulin preparations. persons with selective immunoglobulin a deficiency have the potential for developing antibodies to immunoglobulin a and could have anaphylactic reactions to subsequent administration of blood products that contain immunoglobulin a, including cytogam.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

grifols usa, llc - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - human immunoglobulin g 10 g in 100 ml - gamunex-c is an immune globulin injection (human) 10% liquid that is indicated for the treatment of: gamunex-c is indicated for treatment of primary humoral immunodeficiency in patients 2 years of age and older. this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, x-linked agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies.(1-4) gamunex-c is indicated for the treatment of adults and children with idiopathic thrombocytopenic purpura to raise platelet counts to prevent bleeding or to allow a patient with itp to undergo surgery.(5,6) gamunex-c is indicated for the treatment of cidp in adults to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse. gamunex-c is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. gamunex-c is contraindicated in iga deficient patients with antibodies against iga and history of h